Heparin Al (Heparin Sodium)

Heparin Al is indicated for clinical situations where inhibition of clot formation is required.

• Prevention of deep vein thrombosis (DVT) in patients who are immobilized or have other risk factors.
• Treatment of established venous thromboembolism (VTE), including both deep vein thrombosis and pulmonary embolism.
• Prophylaxis of pulmonary embolism after major orthopedic or abdominal surgery to reduce postoperative clot risk.
• Management of arterial thrombosis during certain cardiovascular interventions, such as percutaneous coronary procedures.
• Adjunctive therapy in patients with atrial fibrillation when rapid anticoagulation is needed to lower stroke risk.

Heparin Al may be associated with a range of adverse effects that vary in frequency and severity.

Common

• Minor bruising or bleeding at the application site.
• Small hematoma formation under the skin.
• Mild itching or local irritation.
• Transient elevation of activated partial thromboplastin time (aPTT) without clinical bleeding.
• Slight redness (erythema) around the injection or application area.
• Temporary swelling at the site.

Serious

• Significant bleeding or hemorrhage at distant sites.
• Heparin-induced thrombocytopenia (HIT) characterized by platelet count drop.
• Allergic reactions such as urticaria, angioedema, or anaphylaxis.
• Spontaneous spinal or epidural hematoma leading to neurologic deficits.
• Disseminated intravascular coagulation (DIC) in rare cases with uncontrolled clotting and bleeding.
• Temporary swelling at the site.

When using Heparin Al, clinicians should evaluate patient-specific factors and follow safety measures to minimize risk.

• Assess baseline coagulation parameters, including aPTT and platelet count, before initiating therapy.
• Adjust dose in patients with renal or hepatic impairment, as clearance may be altered.
• Monitor for signs of bleeding, especially in the gastrointestinal and intracranial regions.
• Avoid use in individuals with known hypersensitivity to heparin or its excipients.
• Use caution in pregnant or nursing women; benefits must outweigh potential risks.
• Reevaluate therapy regularly and discontinue if severe adverse events occur.

Heparin Al can interact with other medications that affect hemostasis or platelet function, requiring careful management.

Avoid

• Concurrent use with other anticoagulants such as warfarin, direct oral anticoagulants, or low‑molecular‑weight heparins.
• Combination with antiplatelet agents like aspirin, clopidogrel, or ticagrelor that markedly increase bleeding risk.
• Simultaneous administration of fibrinolytic drugs (e.g., alteplase) that may cause uncontrolled hemorrhage.

Use with caution

• Non‑steroidal anti‑inflammatory drugs (NSAIDs) or selective COX‑2 inhibitors, which can potentiate bleeding.
• Certain antibiotics (e.g., vancomycin, linezolid) that may alter platelet function.
• Herbal supplements such as ginkgo biloba, garlic, or high‑dose vitamin E that have antithrombotic properties.